1 / 74

Algeria Pharmaceutical Market Analysis Sample Report

This report presents a strategic analysis of the Algeria Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

Algeria Pharmaceutical Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on Algeria Pharmaceutical Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2023 – 2030F) www.insights10.com

  2. This report presents a strategic analysis of the Algeria Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Algeria Pharmaceutical Market, and offers unmatched value, accuracy, and expert insights.

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 06-19 1. Pharmaceutical Overview 1.1. Overview 1.2. Algeria Overview 1.3. Economic Overview: Algeria 1.4. Pharmaceutical Market in Algeria 1.5. Pharmaceuticals Market in Algeria 1.6. Healthcare Scenario in Algeria 1.7. Health Insurance Coverage: Algeria 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 20-26 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 27-31 3. Market Dynamics 3.1. Market Growth Drivers 3.2. Market Restraints 32-42 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 43-48 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 49-54 6. Methodology & Scope 5 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  6. Algeria Pharmaceutical Market Analysis 1. Pharmaceutical Overview

  7. 1.1 Statistics at a Glance: Pharmaceutical Market in the World Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 13.4% Market share was for the drug Humira in 2022 Covid-19 Had a major market share in the pharmaceutical market in 2022 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ US Is the largest market for drugs in 2022 $2499.23 Bn Is the projected global sales figure for pharmaceutical market by 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 55 years Is the average age of patient taking medicine of major market share Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 7 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  8. 1.1 Statistics at a Glance: Pharmaceutical Market in the World (continued) Europe ~Revenue to reach $432.40 Bn by 2030 North America ~ Market Size of $675.13 Bn Asia -Fastest CAGR Africa Algeria ~Market Size of $20.25 Bn ~$2.7 Bn Market Illustrative Illustrative 8 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  9. 1.2 Algeria Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 43.45 Mn Is the population of Algeria, in 2022 269.2 Bn Is the Gross Domestic Product (GDP) in Algeria in 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 31.3 years Is the median age in Algeria, in 2022 $292 Per capita was the amount of national health expenditures in 2022 9 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  10. 1.3 Economic Overview: Algeria Population of Algeria, (2020-2030) GDP of Algeria, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 10 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  11. 1.4 Statistics at a Glance: Pharmaceutical Market in Algeria Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 25% Market share was for the drug Paracetamol in 2022 Hypertension Had a major market share in the pharmaceutical market in 2022 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Algeria ▪ $2.7 Bn Is the global figure for the pharmaceutical market in 2022 70% Of the medicine in Algeria was imported in 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 11 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  12. 1.5 Healthcare Scenario in Algeria Healthcare Infrastructure: Algeria has a public healthcare system that provides free or low-cost healthcare services to its citizens. The country has a network of hospitals, clinics, and healthcare centers, both in urban and rural areas. However, the healthcare infrastructure in rural areas may be limited compared to urban areas Healthcare Funding: The Algerian government allocates a significant portion of its budget to the healthcare sector. The funding is primarily used to support the operation of public healthcare facilities, purchase medical equipment, and provide essential medications Universal Healthcare Coverage: Algeria has implemented a system of universal healthcare coverage, known as the "Caisse Nationale d'Assurance Maladie" (CNAS). The CNAS provides access to healthcare services for the entire population, including employed and unemployed individuals, as well as their dependents Public and Private Sector: The healthcare sector in Algeria consists of both public and private healthcare providers. Public healthcare facilities are generally more accessible and affordable for the majority of the population. However, private healthcare facilities exist, particularly in urban areas, and offer services to those who can afford them Health Challenges: Algeria, like many other countries, faces various health challenges. Some of the common health issues in Algeria include cardiovascular diseases, diabetes, obesity, respiratory diseases, and cancer. The government has been working on improving healthcare infrastructure, implementing disease prevention programs, and promoting healthier lifestyles Healthcare Workforce: Algeria has a significant number of healthcare professionals, including doctors, nurses, and specialists. However, there may be regional disparities in the distribution of healthcare professionals, with urban areas having more resources compared to rural regions Pharmaceutical Industry: Algeria has a domestic pharmaceutical industry that produces a range of medications. The government encourages the local production of essential drugs to ensure their availability and affordability for the population. Additionally, Algeria also imports pharmaceutical products from other countries ▪ ▪ ▪ ▪ ▪ ▪ ▪ 12 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  13. 1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 13 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  14. 1.7 Health Insurance Coverage: Algeria % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 35.7 Any public plan VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Private (18.9%), Public (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ Illustrative Illustrative 14 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  15. 1.8 Budget of Algeria Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Public 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Public spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Private spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 15 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  16. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 16 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  17. 1.9 Mergers and Acquisitions (continued) Latest Deals In Algeria Amount / Duration Company Name Type Year Key Pointers Collaboration will focus on developing a national plan for the prevention and control of non-communicable diseases (NCDs) ▪ Collaboration will aim to reduce the prevalence of NCDs by 25% by 2030 ▪ Collaboration - May, 2022 It is a partnership between the public and private sectors, and it is expected to have a major impact on the health of the Algerian population ▪ Algerian Ministry of Health collaboration with Novartis Acquisition will give Hikma a strong foothold in the Algerian pharmaceutical market, which is the largest in North Africa Hikma expects the acquisition to be accretive to earnings in the first full year of ownership Acquisition of Pharma 5 is a significant move by Hikma as it looks to expand its presence in the Middle East and North Africa (MENA) region. The MENA region is a growing market for generic medicines, and Hikma is well-positioned to capitalize on this growth ▪ ▪ Acquisition $250 Mn March 2022 ▪ Hikma acquisition of Pharma 5 17 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  18. 1.9 Mergers and Acquisitions (continued) Latest Deals In Algeria Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 18 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  19. Algeria Pharmaceutical Market Analysis 2. Market Size and Forecasting

  20. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Algeria Pharmaceutical Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Algeria Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Algeria Market Size (Bn $) 61 74 84 87 91 95 99 106 20 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  21. 2.2 Snapshot of Market Segmentation Brand Therapeutic Area Distribution Channel Domestic Brands Oncology Hospitals Central nervous system International Brands Pharmacies Pain management Retail outlets Cardiovascular Online retailers Respiratory Diabetes Gastrointestinal Anti-infectives Others In this section you will get an understanding of the segmentations which will cover the Algeria Pharmaceutical Market In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ 21 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  22. 2.2.1 Market Segmentation: By Brand Algeria Pharmaceutical Market Share, By Brand (2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Domestic Brands, 45% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ International Brands, 55% Illustrative Illustrative 22 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  23. 2.2.2 Market Segmentation: By Therapeutic Area Algeria Pharmaceutical Market Share, By Therapeutic Area (2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Others Anti-Infectives Oncology Gastrointestinal In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Diabetes Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Central Nervous System Respiratory Cardiovascular Pain Management Illustrative Illustrative 23 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  24. 2.2.3 Market Segmentation: By Distribution Channel Algeria Pharmaceutical Market Share, By Distribution Channel (2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Online Retailers In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Hospitals Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacies Pharmacies Illustrative Illustrative 24 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  25. Algeria Pharmaceutical Market Analysis 3. Market Dynamics

  26. 3.1 Market growth drivers 3.1.1 Prevalence of chronic diseases is increasing in Algeria, according to WHO Cardiovascular diseases and Diabetes are the leading cause of death which accounts for around 31% and 14% of total deaths respectively in Algeria Prevalence of Chronic Diseases in Algeria Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 26 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  27. 3.1 Market growth drivers (continued) 3.1.2 Growing Demand for generic drugs, market share of generic drugs in Algeria accounts for around 75% of the total pharmaceutical market Top countries that are investing in development of generic drugs Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Norway In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Austria Denmark Belgium Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Spain Italy Netherlands Sweden Singapore Switzerland Israel Australia Canada France United Kingdom China South Korea Germany Japan United States 27 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  28. 3.1 Market growth drivers (continued) 3.1.3 Government initiatives and support, the Algerian government has provided tax exemption and subsidy for the production of generic drugs and funding for the development of generic drugs Fundings from the government and other organizations Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Source Year Fund ($) In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ National Cancer Institute (NCI) 2021 $ 6.4 Bn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn American Cancer Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn 28 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  29. 3.2 Market restraints 3.2.1 Complex regulatory system, which increases entry barriers for foreign pharmaceutical companies 3.2.2 Limited access to credit, Algerian banks are reluctant to give loans to pharmaceutical companies 3.2.3 Lack of skilled professionals in Algeria for pharmaceutical companies, which makes it difficult to hire qualified employees Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ ▪ ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. 29 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  30. Algeria Pharmaceutical Market Analysis 4. Competitive Landscape

  31. 4.1 Major Market Share Revenue of Major Players in Algeria Pharmaceutical Market ($ Mn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Other In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ XX Illustrative Illustrative 31 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  32. 4.2 Key Company Profile Key Note: 1 Saidal Here is the list of top 10 companies which will cover in the final report ▪ 2 Sanofi-Aventis Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Sotex o o 4 Pfizer o o 5 AstraZeneca o 6 o Servier o 7 Novartis o 8 MSD ▪ 9 Abbott ▪ 10 Johnson & Johnson 32 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  33. 4.2.1 Saidal Solutions offered by Saidal Founded in: 1982 ▪ Saidal is the largest pharmaceutical company in Algeria and one of the largest in Africa ➢ Generic Drugs HQ: Algiers, Algeria ➢ Over-the-Counter Drugs ▪ In recent years, Saidal has been expanding its production capacity and investing in research and development Type: State-owned ➢ Vaccines ▪ It has also been expanding its export markets Revenue: $1.2 Bn ➢ Clinical Trials ▪ Saidal is well-positioned to continue to grow in the coming years Website: www.saidalgroup. ➢ Research and Development Drugs for Cancer Recent Activity / Press Coverage Drugs In 2023, Saidal announced that it would be investing in a new research and development center Antibiotics Anti-Inflammatory Anti-Cancer Decongestants In 2022, Saidal launched its first bioequivalence center Pain relivers Sleep aids Saidal is also expanding its production capacity in order to meet the growing demand for its products Digestive aids Allergy Medications 33 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  34. 4.2.1 Saidal (continued) Partnership Ecosystem Partnership was initially focused on developing and marketing generic drugs in Algeria. However, it has since expanded to include other areas, such as developing new drugs and transferring technology Saidal Pharmaceuticals and Sinovac Biotech have a partnership to produce the Sinovac COVID-19 vaccine in Algeria. The partnership between Saidal and Sinovac is a significant development for the pharmaceutical industry in Algeria. It will help to ensure that Algeria has a stable supply of the Sinovac vaccine, and it will also help to promote research and development in the pharmaceutical sector. Saidal Pharmaceuticals and Biocad have a partnership to produce the Sputnik V COVID-19 vaccine in Algeria. In addition to the Sputnik V vaccine, Saidal and Biocad are also working on the development of other vaccines, including a vaccine against the Zika virus 34 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  35. 4.2.1 Saidal (continued) Latest Deals - Mergers and Acquisitions Company Name Type Year Key Pointers The partnership between Saidal and Pfizer is a major development for the pharmaceutical industry in Algeria It will help to ensure that Algeria has a stable supply of the Pfizer- BioNTech vaccine, and it will also help to promote research and development in the pharmaceutical sector In addition to the Pfizer-BioNTech COVID-19 vaccine, Saidal and Pfizer are also working on the development of other vaccines, including a vaccine against the Zika virus ▪ ▪ December, 2022 Collaboration Pfizer ▪ Laboratoires du Sud is a leading pharmaceutical company in Algeria, with a strong presence in the generic drug market ▪ Acquisition will give Saidal access to Laboratoires du Sud's manufacturing facilities, product portfolio, and distribution network ▪ Acquisition March 2022 Laboratoires du Sud This will help Saidal to strengthen its position in the Algerian pharmaceutical market and expand its reach into new markets. Laboratoires du Sud has a strong R&D department, and the acquisition will give Saidal access to new technologies and expertise ▪ 35 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  36. 4.2.1 Saidal (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 36 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  37. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications 37 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  38. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners 38 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  39. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers 39 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  40. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 40 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  41. Algeria Pharmaceutical Market Analysis 5. Reimbursement Scenario

  42. 5.1 Reimbursement Regulation Public and Private together provide health insurance coverage for more than 4 in 10 Algerians The reimbursement scenario in the Algerian market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Public: o ▪ Public is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Public covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Private: o Private is a joint federal-state program that provides health insurance for people with low incomes o Private coverage for cancer treatments can vary by state and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 42 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  43. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as cancer Reimbursement for New Treatments: Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 43 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  44. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Public and Private  Public is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Private is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the Algerian healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 44 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  45. 5.2 Reimbursement Process for Diagnosis The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 45 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  46. 5.3 Reimbursement Process for Treatment The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: FDA Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 46 A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential

  47. Algeria Pharmaceutical Market Analysis 6. Methodology & Scope

  48. Research Methodology Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources For forecasting, the following parameters are considered: ❑ Market drivers and restraints along with their current and expected impacts ❑ Technological scenario and expected developments ❑ End use industry trends and dynamics ❑ Trends in the consumer behavior ❑ Regulatory scenario and expected developments ❑ Current capacity and expected capacity additions up to 2030 We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time- sensitive, reflecting the most recent value and volume of the market across regions All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs) Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn) ▪ ▪ ▪ ▪ ▪ ▪ ▪

  49. Analysis Methodology Our Analysis Methodology involves three critical stages: Data Collection Market Data Analysis & Statistical Model Interpretation & Presentation Secondary Research Analysis & Interpretation Market Trends Primary Research Market Sizing & Analysis Insights Proprietary Database Presentation & Reporting Data Triangulation & Validation

  50. Data Triangulation & Data Validation Top Down Approach Final Market Size Final Market size break up to rest of segmentation Validation from Primary Interview Arriving at market size of each segment Summarization of revenue generated from companies to arrive at total market size Validation from Primary Interview Revenue generated by products & services offered by companies Final Summary Bottom Up Approach

More Related